Collagen Sleep Latency Randomized Trial: What the Evidence Says

Quick Answer

Collagen Sleep Latency Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• It is important to gain an understanding of factors associated with poor quality of life as a patient's perception of quality of life can predict treatment and intervention outcomes. [Singh Prachi (2026); evidence level 2]
• While the relationship between insomnia, cardiometabolic risk, and quality of life is recognized, few physicians routinely conduct full sleep histories on their patients, and the patient satisfaction for insomnia treatment remains low. [Singh Prachi (2026); evidence level 2]
• Beyond symptoms and impaired quality of life, OSA has been associated with major cardiometabolic and neurocognitive consequences. [Yuan Sai (2026); evidence level 3]
• Prospective observational evidence links OSA to increased risks of stroke and mortality. [Yuan Sai (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For collagen sleep latency randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Singh Prachi (2026). Effect of an herbal supplement on quality of life in participants with insomnia: A randomized placebo controlled cross-over pilot trial. DOI: 10.1371/journal.pone.0350039. PMCID: PMC13189356. PMID: 42160360. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13189356/
• Yuan Sai (2026). TGF‑β1 in obstructive sleep apnea: linking intermittent hypoxia, upper‑airway remodeling, and systemic comorbidities. DOI: 10.1007/s11325-026-03705-z. PMCID: PMC13171989. PMID: 42126627. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13171989/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.